DOI QR코드

DOI QR Code

Association of Serum HE4 with Primary Tumor Diameter and Depth of Myometrial Invasion in Endometrial Cancer Patients at Rajavithi Hospital

  • Prueksaritanond, Nisa ;
  • Cheanpracha, Patchara ;
  • Yanaranop, Marut
  • Published : 2016.04.11

Abstract

Background: Although there are no biomarkers that are routinely used in endometrial cancer (EC) management, many studies have found that serum human epididymis protein 4 (HE4) is superior to cancer antigen 125 (CA125) in the detection of EC. The correlation of HE4 with two prognostic factors for EC, primary tumor diameter (PTD) and depth of myometrial invasion (DMI) may be useful in identifying EC patients at high risk of lymphatic dissemination. Objective: To evaluate the correlation of serum HE4 with PTD and DMI in patients with EC. Materials and Methods: A cross-sectional study was conducted on 70 EC patients who were scheduled for elective surgery at Rajavithi Hospital between 1st September 2013 and 30th May 2014. Preoperative serum levels of HE4 and CA125 were investigated, and then gross measurement of PTD was taken and postoperative pathologic slides were reviewed for DMI including histologic types, grading and staging. Results: Preoperative serum HE4 levels were strongly correlated with PTD (r=0.65, p<0.001) and moderately correlated with DMI (r=0.46, p<0.001). Moreover, serum HE4 levels were significantly elevated in EC patients with PTD >2 cm (p<0.001) and DMI > 50% (p=0.004). The performance of serum HE4 in identifying EC patients at low risk and high risk of lymph node metastasis was significantly better than that of CA125 (AUC 0.88 vs. 0.65, p=0.003). At an optimal cut-off value of 70 pM/L, serum HE4 had a sensitivity of 83.3% and a specificity of 80.0%. Conclusions: In EC patients, preoperative serum HE4 is significantly correlated with PTD and DMI. Serum HE4 levels could be useful in identifying endometrial cancer patients at high risk of lymphatic spread who would benefit from systemic lymphadenectomy at the cut-off value of 70 pM/L.

Keywords

Endometrial cancer;human epididymis protein 4;CA125;primary tumor diameter;myometrial invasion

References

  1. Ali A, Black D, Soslow RA (2007). Difficulties in assessing the depth of myometrial invasion in endometrial carcinoma. Int J Gynecol Pathol, 26, 115-23. https://doi.org/10.1097/01.pgp.0000233165.56385.0b
  2. Angioli R, Plotti F, Capriglione S, et al (2013). The role of novel biomarker HE4 in endometrial cancer: a case control prospective study. Tumour Biol, 34, 571-6. https://doi.org/10.1007/s13277-012-0583-0
  3. Antonsen SL, Hogdall E, Christensen IJ, et al (2013). HE4 and CA125 levels in the preoperative assessment of endometrial cancer patients: a prospective multicenter study (ENDOMET). Acta Obstet Gynecol Scand, 92, 1313-22. https://doi.org/10.1111/aogs.12235
  4. Bignotti E, Ragnoli M, Zanotti L, et al (2011). Diagnostic and prognostic impact of serum HE4 detection in endometrial carcinoma patients. Br J Cancer, 104, 1418-25. https://doi.org/10.1038/bjc.2011.109
  5. Bolstad N, Oijordsbakken M, Nustad K, et al (2012). Human epididymis protein 4 reference limits and natural variation in a Nordic reference population. Tumour Biol, 33, 141-8. https://doi.org/10.1007/s13277-011-0256-4
  6. Brennan DJ, Hackethal A, Metcalf AM, et al (2014). Serum HE4 as a prognostic marker in endometrial cancer--a population based study. Gynecol Oncol, 132, 159-65. https://doi.org/10.1016/j.ygyno.2013.10.036
  7. Cancer in Thailand (2010). Bangkok, Ministry of public health.
  8. Creasman WT, Odicino F, Maisonneuve P, et al (2006). Carcinoma of the corpus uteri. FIGO 26th Annual Report on the Results of Treatment in Gynecological Cancer. Int J Gynaecol Obstet, 95, 105-43. https://doi.org/10.1016/S0020-7292(06)60031-3
  9. Drapkin R, von Horsten HH, Lin Y, et al (2005). Human epididymis protein 4 (HE4) is a secreted glycoprotein that is overexpressed by serous and endometrioid ovarian carcinomas. Cancer Res, 65, 2162-9. https://doi.org/10.1158/0008-5472.CAN-04-3924
  10. Jemal A, Siegel R, Ward E, et al (2008). Cancer statistics. CA Cancer J Clin, 58, 71-96. https://doi.org/10.3322/CA.2007.0010
  11. Jhang H, Chuang L, Visintainer P, et al (2003). CA 125 levels in the preoperative assessment of advanced-stage uterine cancer. Am J Obstet Gynecol, 188, 1195-7. https://doi.org/10.1067/mob.2003.304
  12. Kalogera E, Scholler N, Powless C, et al (2012). Correlation of serum HE4 with tumor size and myometrial invasion in endometrial cancer. Gynecol Oncol, 124, 270-5. https://doi.org/10.1016/j.ygyno.2011.10.025
  13. Mariani A, Dowdy SC, Cliby WA, et al (2008). Prospective assessment of lymphatic dissemination in endometrial cancer: a paradigm shift in surgical staging. Gynecol Oncol, 109, 11-8. https://doi.org/10.1016/j.ygyno.2008.01.023
  14. Mariani A, Webb MJ, Keeney GL, et al (2000). Low-risk corpus cancer: is lymphadenectomy or radiotherapy necessary?. Am J Obstet Gynecol, 182, 1506-19. https://doi.org/10.1067/mob.2000.107335
  15. Moore RG, Brown AK, Miller MC, et al (2008). Utility of a novel serum tumor biomarker HE4 in patients with endometrioid adenocarcinoma of the uterus. Gynecol Oncol, 110, 196-201. https://doi.org/10.1016/j.ygyno.2008.04.002
  16. Moore RG, Miller CM, Brown AK, et al (2011). Utility of tumor marker HE4 to predict depth of myometrial invasion in endometrioid adenocarcinoma of the uterus. Int J Gynecol Cancer, 21, 1185-90.
  17. Movahedi-Lankarani S, Gilks C, Soslow R, et al (2009). Protocol for the examination of specimens from patients with carcinoma of the endometrium. college of american pathologists (CAP).
  18. Mutz-Dehbalaie I, Egle D, Fessler S, et al (2012). HE4 is an independent prognostic marker in endometrial cancer patients. Gynecol Oncol, 126, 186-91. https://doi.org/10.1016/j.ygyno.2012.04.022
  19. Powell JL, Hill KA, Shiro BC, et al (2005). Preoperative serum CA-125 levels in treating endometrial cancer. J Reprod Med, 50, 585-90.
  20. Takeshima N, Shimizu Y, Umezawa S, et al (1994). Combined assay of serum levels of CA125 and CA19-9 in endometrial carcinoma. Gynecol Oncol, 54, 321-6. https://doi.org/10.1006/gyno.1994.1217
  21. Trovik J, Mauland KK, Werner HM, Wik E, et al (2012). Improved survival related to changes in endometrial cancer treatment, a 30-year population based perspective. Gynecol Oncol, 125, 381-7. https://doi.org/10.1016/j.ygyno.2012.01.050
  22. Vargas R, Rauh-Hain JA, Clemmer J, et al (2014). Tumor size, depth of invasion, and histologic grade as prognostic factors of lymph node involvement in endometrial cancer: a SEER analysis. Gynecol Oncol, 133, 216-20. https://doi.org/10.1016/j.ygyno.2014.02.011
  23. Youden WJ (1950). Index for rating diagnostic tests. Cancer, 3, 32-5. https://doi.org/10.1002/1097-0142(1950)3:1<32::AID-CNCR2820030106>3.0.CO;2-3

Cited by

  1. Discovery of biomarkers for endometrial cancer: current status and prospects vol.16, pp.12, 2016, https://doi.org/10.1080/14737159.2016.1258302
  2. HE4-test of urine and body fluids for diagnosis of gynecologic cancer vol.17, pp.3, 2017, https://doi.org/10.1080/14737159.2017.1282824
  3. Human Epididymis Protein 4 Promotes Events Associated with Metastatic Ovarian Cancer via Regulation of the Extracelluar Matrix vol.7, pp.2234-943X, 2018, https://doi.org/10.3389/fonc.2017.00332
  4. Beyond the Biomarker: Understanding the Diverse Roles of Human Epididymis Protein 4 in the Pathogenesis of Epithelial Ovarian Cancer vol.8, pp.2234-943X, 2018, https://doi.org/10.3389/fonc.2018.00124